Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25749124 | 0.81 | L3MBTL1 (0.42) | L3MBTL1NUDT1TNKS | |
| SCHEMBL25527594 | 0.81 | L3MBTL1 (0.59) | L3MBTL1NUDT1TNKS | |
| SCHEMBL20801915 | 0.80 | L3MBTL1 (0.39) | L3MBTL1NUDT1TNKS | |
| SCHEMBL20125020 | 0.79 | L3MBTL1 (0.41) | L3MBTL1NUDT1TNKS | |
| SCHEMBL20124995 | 0.77 | L3MBTL1 (0.49) | L3MBTL1NUDT1TNKS | |
| SCHEMBL24087286 | 0.76 | L3MBTL1 (0.43) | L3MBTL1NUDT1TNKS | |
| SCHEMBL20801724 | 0.73 | METAP2 (0.40) | L3MBTL1 | |
| SCHEMBL25310988 | 0.73 | NUDT1 (0.45) | L3MBTL1NUDT1TNKS | |
| SCHEMBL1348141 | 0.73 | L3MBTL1 (0.62) | L3MBTL1NUDT1TNKS | |
| SCHEMBL15828611 | 0.72 | TNKS (0.43) | L3MBTL1NUDT1TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3318557-A2 | QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | L3MBTL1 2548/4885NUDT1 483/4885TNKS 19/4885 |
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | L3MBTL1 2941/4885NUDT1 1266/4885TNKS 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.